TVRD

Tvardi Therapeutics, Inc. Common Stock

24.94 USD
+1.94
8.43%
At close Apr 30, 4:00 PM EDT
After hours
26.00
+1.06
4.25%
1 day
8.43%
5 days
50.15%
1 month
391.91%
3 months
397.80%
6 months
618.73%
Year to date
365.30%
1 year
176.50%
5 years
-85.98%
10 years
-80.67%
 

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

58% more capital invested

Capital invested by funds: $4.17M [Q3] → $6.59M (+$2.42M) [Q4]

41% less funds holding

Funds holding: 70 [Q3] → 41 (-29) [Q4]

82% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 34

97% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 33

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$39
56%
upside
Avg. target
$39
56%
upside
High target
$39
56%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Jones Trading
Debanjana Chatterjee
43% 1-year accuracy
3 / 7 met price target
56%upside
$39
Buy
Initiated
28 Apr 2025

Financial journalist opinion

Charts implemented using Lightweight Charts™